Terms: = Breast cancer AND HOXA9, HOX1, 3205, ENSG00000078399, HOX1G, P31269
29 results:
1. Longitudinal adherence to surveillance for late effects of cancer treatment: a population-based study of adult survivors of childhood cancer.
Shuldiner J; Sutradhar R; Lau C; Shah N; Lam E; Ivers N; Nathan PC
CMAJ; 2024 Mar; 196(9):E282-E294. PubMed ID: 38467416
[TBL] [Abstract] [Full Text] [Related]
2. Fatal and non-fatal breast cancers in women targeted by breastScreen Norway: a cohort study.
Tsuruda KM; Hoff SR; Akslen LA; Hofvind S
Br J Cancer; 2024 Jan; 130(1):99-107. PubMed ID: 38049556
[TBL] [Abstract] [Full Text] [Related]
3. Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA.
Kjær IM; Kahns S; Timm S; Andersen RF; Madsen JS; Jakobsen EH; Tabor TP; Jakobsen A; Bechmann T
Sci Rep; 2023 May; 13(1):8419. PubMed ID: 37225860
[TBL] [Abstract] [Full Text] [Related]
4. In silico analysis of differentially expressed-aberrantly methylated genes in breast cancer for prognostic and therapeutic targets.
Gadwal A; Purohit P; Khokhar M; Vishnoi JR; Pareek P; Choudhary R; Elhence P; Banerjee M; Sharma P
Clin Exp Med; 2023 Nov; 23(7):3847-3866. PubMed ID: 37029310
[TBL] [Abstract] [Full Text] [Related]
5. E2F1 Affects the Therapeutic Response to Neoadjuvant Therapy in breast cancer.
Ye X; Zhou J; Tong D; Wang D; Wang H; Guo J; Kang X
Dis Markers; 2022; 2022():8168517. PubMed ID: 36164372
[TBL] [Abstract] [Full Text] [Related]
6. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; ; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C
Gynecol Oncol; 2021 Sep; 162(3):720-727. PubMed ID: 34454680
[TBL] [Abstract] [Full Text] [Related]
7. MicroRNA-638 inhibits the progression of breast cancer through targeting hoxa9 and suppressing Wnt/β-cadherin pathway.
Xu Q; Zhang Q; Dong M; Yu Y
World J Surg Oncol; 2021 Aug; 19(1):247. PubMed ID: 34416888
[TBL] [Abstract] [Full Text] [Related]
8. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract] [Full Text] [Related]
9. A long-range interactive DNA methylation marker panel for the promoters of hoxa9 and HOXA10 predicts survival in breast cancer patients.
Park SM; Choi EY; Bae M; Choi JK; Kim YJ
Clin Epigenetics; 2017; 9():73. PubMed ID: 28748001
[TBL] [Abstract] [Full Text] [Related]
10. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment.
Shafat MS; Oellerich T; Mohr S; Robinson SD; Edwards DR; Marlein CR; Piddock RE; Fenech M; Zaitseva L; Abdul-Aziz A; Turner J; Watkins JA; Lawes M; Bowles KM; Rushworth SA
Blood; 2017 Mar; 129(10):1320-1332. PubMed ID: 28049638
[TBL] [Abstract] [Full Text] [Related]
11. Induction of hoxa9 expression in three-dimensional organotypic culture of the Claudin-low breast cancer cells.
Li M; Li X; Zhuang Y; Wang Y; Burow ME; Collins-Burow B; Xue M; Song C; Shan B
Oncotarget; 2016 Aug; 7(32):51503-51514. PubMed ID: 27409175
[TBL] [Abstract] [Full Text] [Related]
12. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers.
Li L; Li C; Mao H; Du Z; Chan WY; Murray P; Luo B; Chan AT; Mok TS; Chan FK; Ambinder RF; Tao Q
Sci Rep; 2016 May; 6():26591. PubMed ID: 27225590
[TBL] [Abstract] [Full Text] [Related]
13. DNA methylation profiling in the Carolina breast cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.
Conway K; Edmiston SN; May R; Kuan PF; Chu H; Bryant C; Tse CK; Swift-Scanlan T; Geradts J; Troester MA; Millikan RC
Breast Cancer Res; 2014 Oct; 16(5):450. PubMed ID: 25287138
[TBL] [Abstract] [Full Text] [Related]
14. TNBC vs non-TNBC: A retrospective review of differences in mean age, family history, smoking history, and stage at diagnosis.
Tariq K; Farhangi A; Rana F
Clin Adv Hematol Oncol; 2014 Jun; 12(6):377-81. PubMed ID: 25003567
[TBL] [Abstract] [Full Text] [Related]
15. HOX genes and their role in the development of human cancers.
Bhatlekar S; Fields JZ; Boman BM
J Mol Med (Berl); 2014 Aug; 92(8):811-23. PubMed ID: 24996520
[TBL] [Abstract] [Full Text] [Related]
16. Poly(ADP-ribosyl)ation is involved in the epigenetic control of TET1 gene transcription.
Ciccarone F; Valentini E; Bacalini MG; Zampieri M; Calabrese R; Guastafierro T; Mariano G; Reale A; Franceschi C; Caiafa P
Oncotarget; 2014 Nov; 5(21):10356-67. PubMed ID: 24939750
[TBL] [Abstract] [Full Text] [Related]
17. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression.
Mouw JK; Yui Y; Damiano L; Bainer RO; Lakins JN; Acerbi I; Ou G; Wijekoon AC; Levental KR; Gilbert PM; Hwang ES; Chen YY; Weaver VM
Nat Med; 2014 Apr; 20(4):360-7. PubMed ID: 24633304
[TBL] [Abstract] [Full Text] [Related]
18. miR-126 in human cancers: clinical roles and current perspectives.
Ebrahimi F; Gopalan V; Smith RA; Lam AK
Exp Mol Pathol; 2014 Feb; 96(1):98-107. PubMed ID: 24368110
[TBL] [Abstract] [Full Text] [Related]
19. HMGA2/TET1/hoxa9 signaling pathway regulates breast cancer growth and metastasis.
Sun M; Song CX; Huang H; Frankenberger CA; Sankarasharma D; Gomes S; Chen P; Chen J; Chada KK; He C; Rosner MR
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9920-5. PubMed ID: 23716660
[TBL] [Abstract] [Full Text] [Related]
20. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract] [Full Text] [Related]
[Next]
